Nature Biotech

Nature Biotechnology - Issue - nature.com science feeds

Nature Biotechnology journal featuring biotechnology articles and science research papers of commercial interest in pharmaceutical, medical, and environmental sciences.

Wrong numbers?

With biotech infiltrating multiple industries and fewer life science ventures listing on stock exchanges, what do we really learn from surveying the set of public biotech companies?
 

MAQC-II: analyze that!

The MAQC consortium's latest study suggests that human error in handling DNA microarray data analysis software could delay the technology's wider adoption in the clinic.
 

Industry makes strides in melanoma

 

Firms combine experimental cancer drugs to speed development

 

Supremes rule on Bilski

 

FDA transparency rules could hit small companies hardest

 

Lawsuits rock Jackson

 

Anti-CD20 patent battle ends

 

EU states free to ban GM crops

 

Food firms test fry Pioneer's trans fat?free soybean oil

 

GM alfalfa?who wins?

 

Biofuel 'Made in China'

 

2Q10?spreading the wealth

 

Drugmakers dance with autism

With monogenetic neurodevelopmental disorders similar to autism serving as starting points for several drug discovery programs, smaller biotechs are now joining big pharma in pursuing therapies to tackle this perplexing condition. Sarah Webb reports.
 

At ground level

The hardest?and perhaps loneliest?period of being an entrepreneur might be just after your company is founded.
 

Waking up and smelling the coffee

 

Reply to Waking up and smelling the coffee

 

Genetic stability in two commercialized transgenic lines (MON810)

 

Distances needed to limit cross-fertilization between GM and conventional maize in Europe

 

Case study: India's billion dollar biotech

By focusing on an unmet medical need, providing a cost-efficient solution and reinvesting the resulting revenues into R&D and state-of-the-art manufacturing, Shantha Biotechnics was able to build one of India's first biotech successes.
 

DNA patents and diagnostics: not a pretty picture

Restrictive licensing practices on DNA patents are stymieing clinical access and research on genetic diagnostic testing. Diagnostic companies, university tech transfer offices and their respective associations need to pay more attention.
 

Public biotech 2009?the numbers

The public biotech sector sustained more losses in 2009, but the year ended on a positive note, and the industry has regained its footing.
 

Bilski v. Kappos: the US Supreme Court broadens patent subject-matter eligibility

The court narrowly ruled that business methods may be patent eligible, while striking down the primacy of its main test.
 

Recent patent applications in proteomics

 

Can HIV be cured with stem cell therapy?

Transplantation of human hematopoietic stem cells engineered to lack the viral coreceptor CCR5 confers resistance to HIV infection in mice.